
PORTFOLIO
WE TARGET HEALTHCARE ASSETS WITH SIGNIFICANT CLINICAL VALUE AND STRONG BARRIERS TO ENTRY
that are marketed by some of the world’s largest pharmaceutical companies. We also look for assets that will produce sustainable revenues over an extended period of time. Our investments span the pharmaceutical, biotechnology and specialty pharmaceutical sectors.
Royalty Monetization
EA Pharma Co., Ltd
ROYALTY MONETIZATION $60 Million
Jun 2020 / Dec 2017
GOOFICE<sup>®</sup>(elobixibat)Corporate Financing
NEXLETOL©, NEXLIZET©, ENBUMYST©
Senior Debt
$150 Million /
$25M Acquisition Financing
APR 2026 / Dec 2024
Esperion
YUTREPIA™, Treprostinil
Non-Dilutive Financing Up to $200 Million
MAR 2025 / SEP 2024 / JAN 2024 / JUL 2023 / JAN 2023
Liquidia
XIPERE, ARVN001, RGX-314, AU-011
ROYALTY MONETIZATION Up to $65 Million
Aug 2022
Clearside Biomedical
Movantik®, Talicia®, Aemcolo®
Senior Secured Debt with fixed and contingent interest Up to $115 Million
Feb 2020
RedHill Biopharma Ltd.
GIAPREZA™ (angiotensin II)
Synthetic Royalty™ Financing $125 million
May 2018
La Jolla Pharmaceutical Company